Global X S&P Biotech ETF (ASX:CURE)
Australia · Delayed Price · Currency is AUD 65.48
-0.09 (-0.14%)
Apr 21, 2026, 4:10 PM AEST
60.69% (1Y)
| Assets | 41.74M |
| Expense Ratio | 0.45% |
| PE Ratio | n/a |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| 1-Year Return | +60.69% |
| Volume | 1,238 |
| Open | 65.80 |
| Previous Close | 65.57 |
| Day's Range | 65.26 - 65.80 |
| 52-Week Low | 40.08 |
| 52-Week High | 65.95 |
| Beta | 0.33 |
| Holdings | 10 |
| Inception Date | Nov 8, 2018 |
About CURE
The Global X S&P Biotech ETF (CURE) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the S&P Biotechnology Select Industry Index.
Asset Class Equity
Category Health Care
Stock Exchange Australian Securities Exchange
Ticker Symbol CURE
Provider Global X
Index Tracked S&P Biotechnology Select Industry
Performance
CURE had a total return of 60.69% in the past year, including dividends. Since the fund's inception, the average annual return has been 7.24%.
Top Holdings
14.10% of assets| Name | Symbol | Weight |
|---|---|---|
| Apellis Pharmaceuticals, Inc. | APLS | 1.72% |
| Revolution Medicines, Inc. | RVMD | 1.57% |
| Summit Therapeutics Inc. | SMMT | 1.52% |
| Travere Therapeutics, Inc. | TVTX | 1.45% |
| Twist Bioscience Corporation | TWST | 1.34% |
| TG Therapeutics, Inc. | TGTX | 1.32% |
| Alkermes plc | ALKS | 1.31% |
| Apogee Therapeutics, Inc. | APGE | 1.30% |
| Madrigal Pharmaceuticals, Inc. | MDGL | 1.30% |
| Beam Therapeutics Inc. | BEAM | 1.27% |